» Articles » PMID: 32507551

Prevalence of NAFLD in Guatemala Following Exposure to a Protein-energy Nutrition Intervention in Early Life

Overview
Journal Ann Hepatol
Specialty Gastroenterology
Date 2020 Jun 9
PMID 32507551
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction And Objectives: The global prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 25%, with Hispanic populations at greatest risk. We describe the prevalence of NAFLD in a cohort of Guatemalan adults and examine whether exposure to a protein-energy supplement from conception to two years is associated with lower prevalence of NAFLD.

Materials And Methods: From 1969 to 1977, four villages in Guatemala were cluster-randomized to receive a protein-energy supplement (Atole) or a no-protein, low-energy beverage (Fresco). We conducted a follow-up of participants from 2015 to 2017. We assessed blood samples (n=1093; 61.1% women; aged 37-53 years) for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and estimated NAFLD prevalence using the liver fat score. We used generalized linear and logistic models to estimate the difference-in-difference effect of Atole from conception to two years on NAFLD.

Results: Median ALT and AST were 19.7U/L (interquartile range, IQR: 14.1, 27.4) and 26.0U/L (IQR: 21.4, 32.8), respectively. The median NAFLD liver fat score was 0.2 (IQR: -1.2, 1.6) in women and -1.2 (IQR: -2.2, 0.5) in men (p<0.0001). The prevalence of NAFLD was 67.4% among women and 39.5% among men (p<0.0001). The association between Atole exposure from conception to two years and NAFLD was not significant (OR: 0.90, 95% CI: 0.50-1.63).

Conclusions: NAFLD prevalence among Guatemalan adults exceeds the global average. Protein-energy supplementation in early life was not associated with later NAFLD. There is a need for further studies on the causes and onset of NAFLD throughout the life course.

Citing Articles

Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala.

Rivera-Andrade A, Petrick J, Alvarez C, Graubard B, Florio A, Kroker-Lobos M Aliment Pharmacol Ther. 2022; 56(2):321-329.

PMID: 35484638 PMC: 9233027. DOI: 10.1111/apt.16948.

References
1.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

2.
Sandboge S, Perala M, Salonen M, Blomstedt P, Osmond C, Kajantie E . Early growth and non-alcoholic fatty liver disease in adulthood-the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Ann Med. 2013; 45(5-6):430-7. DOI: 10.3109/07853890.2013.801275. View

3.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

4.
Machado M, Cortez-Pinto H . Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2012; 58(5):1007-19. DOI: 10.1016/j.jhep.2012.11.021. View

5.
Breij L, Kerkhof G, Hokken-Koelega A . Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. J Clin Endocrinol Metab. 2014; 99(4):1189-95. DOI: 10.1210/jc.2013-3199. View